Bristol-myers Squibb Compnay

Universitéde Montreal

Jeremy M Richter

Eldon Scott Priestley

Xiaojun Zhang

Oz Scott Halpern

Samuel Kaye Reznik

Manoranjan Panda

Prashantha Gunaga

Navnath Dnyanoba Yadav

Rajeev S Bhide

Rajesh Onkardas Bora

Wen Jiang

J Alex Bates

Edward H Ruediger

Wu Yang

Rejean Ruel

Sasmita Tripathy

Qinghong Fu

Daniel L Cheney

Sreenivasulu Godesi

Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein Ris a bicyclic heteroaryl group substituted with zero to 3 R; and R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Bicyclic heteroaryl substituted compounds

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Biarylmethyl heterocycles

Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein Ris a tricyclic heteroaryl group substituted with Rand zero to 2 R; and R, R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors

Disclosed are compounds of Formula (I) or a salt thereof,wherein Ris: each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, R, L, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

Substituted nitrogen containing compounds

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or &#x3b2;-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CRor N; Y is CRor N, provided that Y is N only if X is N; Ris Formulae (A) or (B); each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, L, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases. 

Substituted bicyclic heterocyclic compounds

Disclosed are compounds of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein Ris a monocyclic heteroaryl group substituted with zero to 3 R; and R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. 

Monocyclic heteroaryl substituted compounds

Disclosed are compounds of Formula (I) to (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. 

Disclosed are compounds of Formula (I) or a salt thereof, wherein Ris (II) or (III); each W is independently NRor O; Z is a bond or CHR; and R, R, R, R, L, L, R, R, R, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases. 

Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors

The present invention provides compounds of Formula (I) wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments. 

3-sulfonyl-5-aminopyridine-2,4-diol APJ agonists

The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments. 

Growing community of inventors

Ewing, NJ, United States of America

Jeremy M Richter